Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once-weekly dosing

Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial

(2021) Harpreet S. Bajaj et al.   DIABETES CARE

237-OR: Insulin Icodec: An Insulin Analog Suited for Once-Weekly Dosing in Type 2 Diabetes

(2020) ULRIKE HÖVELMANN et al.   DIABETES

Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment

(2020) Julio Rosenstock et al.   NEW ENGLAND JOURNAL OF MEDICINE

Engineering of Orally Available, Ultralong-Acting Insulin Analogues: Discovery of OI338 and OI320

(2020) Thomas B. Kjeldsen et al.   JOURNAL OF MEDICINAL CHEMISTRY

Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial

(2019) Inge B Halberg et al.   Lancet Diabetes & Endocrinology

The Discovery and Development of Liraglutide and Semaglutide

(2019) Lotte Bjerre Knudsen et al.   Frontiers in Endocrinology

Plasma insulin profiles after subcutaneous injection: how close can we get to physiology in people with diabetes?

(2015) P. D. Home   DIABETES OBESITY & METABOLISM

Glycaemic control of Type 1 diabetes in clinical practice early in the 21st century: an international comparison

(2015) J. A. McKnight et al.   DIABETIC MEDICINE

Geographic patterns in patient demographics and insulin use in 18 countries, a global perspective from the multinational observational study assessing insulin use: understanding the challenges associated with progression of therapy (MOSAIc)

(2015) Jennifer M. Polinski et al.   BMC Endocrine Disorders

Comparative effectiveness of vildagliptin in combination with other oral anti-diabetes agents in usual-care conditions: the EDGE–Latin America study

(2014) Carlos O. Mendivil et al.   CURRENT MEDICAL RESEARCH AND OPINION

Albumin as a versatile platform for drug half-life extension

(2013) Darrell Sleep et al.   BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS

Albumin–drug interaction and its clinical implication

(2013) Keishi Yamasaki et al.   BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS

Clinical outcomes after 24 months of insulin therapy in patients with type 2 diabetes in five countries: results from the TREAT study

(2013) A. Oguz et al.   CURRENT MEDICAL RESEARCH AND OPINION

Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study

(2012) M. Peyrot et al.   DIABETIC MEDICINE

Systematic Evaluation of the Metabolic to Mitogenic Potency Ratio for B10-Substituted Insulin Analogues

(2012) Tine Glendorf et al.   PLoS One

Molecular Characterisation of Long-Acting Insulin Analogues in Comparison with Human Insulin, IGF-1 and Insulin X10

(2012) Bo F. Hansen et al.   PLoS One

Patient perspectives on once-weekly medications for diabetes

(2010) W. H. Polonsky et al.   DIABETES OBESITY & METABOLISM

In Vitro Metabolic and Mitogenic Signaling of Insulin Glargine and Its Metabolites

(2010) Mark R. Sommerfeld et al.   PLoS One

Albumin as Fatty Acid Transporter

(2009) Ger J. van der Vusse   Drug Metabolism and Pharmacokinetics

MCF-7 human mammary adenocarcinoma cells exhibit augmented responses to human insulin on a collagen IV surface

(2009) Nicolai Listov-Saabye et al.   JOURNAL OF APPLIED TOXICOLOGY

10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes

(2008) Rury R. Holman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Identification of High Affinity Fatty Acid Binding Sites on Human Serum Albumin by MM-PBSA Method

(2007) Shin-ichi Fujiwara et al.   BIOPHYSICAL JOURNAL